ZICOH® Technology by Vivera Granted Second U.S. Patent (US 11,090,449) for Smart Inhaler Device
NEWPORT BEACH, Calif. – The U.S. Patent and Trademark Office (USPTO) has granted Vivera’s ZICOH® technology a second U.S. Patent, No. 11,090,449. Vivera is pleased to
Vivera Pharmaceuticals Receives U.S. Patent (US 11,083,850) for ZICOH®
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc. (Vivera) today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,083,850 for ZICOH®,
Vivera Pharmaceuticals Responds to New Safety Protocols with Expanded Access to COVID-19 Testing, Vaccines, and Personal Protective Equipment
NEWPORT BEACH, Calif. – In response to new nationwide mask and testing mandates, Vivera Pharmaceuticals has expanded access to testing resources, vaccine clinics, and personal
Vivera Pharmaceuticals Supports Naomi Osaka’s Stance On Prioritizing Mental Health
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., an innovative, science-driven pharmaceutical company founded on the belief that patients should always come first, recognizes that mental health
Vivera Pharmaceuticals Congratulates Partner Clinical Research Organization, Parexel International, on $8.5 Billion Acquisition by Goldman Sachs
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., congratulates its clinical research partner, Parexel International, on its $8.5 billion acquisition. The EQT IX fund and the
Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc. and diagnostic testing distributor, Areum Bio LLC, today announce their channel partnership to expand the distribution of Access Bio,
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
